<DOC>
	<DOCNO>NCT01471821</DOCNO>
	<brief_summary>This prospective , open control trial HIV-1 viral suppression patient randomize continue current treatment ( lopinavir/ritonavir plus emtricitabine lamivudine plus nucleoside analogue reverse transcriptase inhibitor ) simplify lopinavir/ritonavir plus lamivudine . Randomization stratify accord value nadir CD4 time viral suppression .</brief_summary>
	<brief_title>Study Evaluate Activity Tolerability Lopinavir/Ritonavir Lamivudine Bitherapy HIV Patients With Viral Suppression</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>Patients either sex ( female male ) 18 year old . Patients seropositive HIV1 use standard diagnostic criterion . There confirmation viral load lower 50 cop/ml 6 previous month inclusion . The requirement least two viral load low 50 cop/mL separate 6 month one &gt; 50cop/mL 6 month inclusion . Patients continuous HAART consist LPV/r , emtricitabine ( FTC ) 3TC ( lamivudine ) NRTI least 2 month randomize study . Patients clinically stable , opinion investigator , entry study ( clinical status chronic medication must modify least 14 day prior randomization ) . Patients receive therapy active opportunistic infection eligible enrollment criterion meet . Standard prophylaxis opportunistic infection permit . Pregnancy , nursing , plan pregnancy study period . Previous failure regimens include protease inhibitor ( PI ) 3TC/FTC . Known resistance mutation PIs 3TC/FTC . Patients active opportunistic infection malignancy . Patients stable chronic opportunistic infection may include study . Any disease history disease , opinion investigator , might confound result study pose additional risk patient treatment . Patients diagnose visceral Kaposi 's sarcoma ( KS ) , patient lymphoedema secondary cutaneous KS cutaneous palatine KS treat systemic immunosuppressive therapy must also exclude . Patients chronic hepatitis B treatment tenofovir + 3TC/FTC</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>